VacZine Analytics  
MarketVIEW: Smoking cessation (nicotine) vaccines

Now part of MasterVIEW 2020
Click here>>

In 2010, there were an estimated 600 million daily tobacco smokers in the major Western + BRIC (Emerging markets). According to the WHO, tobacco kills nearly six million people each year, of whom more than 5 million are users and ex users and more than 600 000 are nonsmokers exposed to second-hand smoke. Nearly 80% of the world's one billion smokers live in low- and middle-income countries.

Many smokers want to quit and several pharmacologic therapies for smoking cessation are available which can enhance quit rates. These include direct nicotine replacement therapy (NRT), varenicline (Chantix) and bupropion (Zyban). Nicotine vaccines are also being investigated which induce antibodies which bind nicotine in the blood preventing it from crossing the blood-brain barrier. However, failure rate has been high with NABI's (GSK) NicVAX, Cytos's NicQb/NIC002 and Celtic Pharma's TA-NIC all being discontinued.

This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of smoking cessation nicotine vaccines across major Western1 and BRIC-MT markets until 2030. The model contains value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for target populations. The product also includes an in depth review of latest smoking epidemiological trends, cessation treatments and latest developments in R&D.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV044 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2013 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains